Company Overview of Ability Pharmaceuticals, S.L.
Ability Pharmaceuticals, S.L., a clinical stage drug discovery and development biopharmaceutical company, develops human therapeutics to treat cancer and other indications with unmet medical needs. The company focuses in the treatment of lung, pancreatic, and gynecological cancers. It offers Lipid Analogue Therapeutics, a new novel drug class of small molecules administered to patients by oral route. The company’s development pipeline includes ABTL0812, an inhibitor of the Akt/mTOR signaling pathways; and ABTL0815, a drug candidate in preclinical characterization. It develops new drug candidates up to clinical proof of concept and later out-licenses them to pharmaceutical companies for furth...
Campus de la UAB
Founded in 2009
Key Executives for Ability Pharmaceuticals, S.L.
Co-Founder, Chief Executive Officer and Director
Secretary General and Director
Vice-President of Research & Development
Director of Clinical Research
Compensation as of Fiscal Year 2017.
Ability Pharmaceuticals, S.L. Key Developments
Ability Pharmaceuticals SL Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer
Dec 13 17
Ability Pharmaceuticals SL announced that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application which allows AbilityPharma to proceed with a phase 1/2a clinical trial of ABTL0812, its autophagy inducer via PI3K/Akt/mTOR pathway inhibition, in patients with endometrial cancer or squamous non-small cell lung cancer, in combination with paclitaxel and carboplatin as first-line therapy. AbilityPharma submitted its IND on October 31, 2017. The trial is ongoing in Europe, where a total of 80 patients will be enrolled. Since November 2016, patients are being included in Vall d'Hebron Institute of Oncology VHIO (Barcelona), Institut CatalÃ d'Oncologia ICO (L'Hospilatet, Badalona and Girona in Catalonia), INCLIVA (ValÃ¨ncia) and Hospital Universitario Virgen del RocÃo (Sevilla). In early 2018 the trial will start recruiting patients in Institut Gustave Roussy (Paris), Centre LÃ©on BÃ©rard (Lyon) and Institut Paoli-Calmettes (Marseille), following the Clinical Trial Application (CTA) approval in France in October 2017. ABTL0812 causes autophagy-mediated cell death through the overexpression of TRIB3, a protein regulating Akt. It is a first-in-class, fully differentiated oral targeted anticancer compound inhibiting the PI3K/Akt/mTOR pathway without being a direct kinase inhibitor. In preclinical cancer models ABTL0812 is efficacious as single agent with outstanding safety profile in a broad spectrum of cancer types. It also has synergistic effect with chemotherapy without increasing its toxicity. In phase 1, ABTL0812 had excellent safety and tolerability compared to other inhibitors of the pathway, without dose-limiting toxicities. Remarkably 2 patients had extremely long disease stabilizations over one year (14 and 18 months). Additionally, ABTL0812 showed high efficacy on biomarkers of the pathway, with dose-response effect.
Ability Pharmaceuticals, S.L. Presents at Sachs Associates 17th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-26-2017 04:30 PM
Sep 20 17
Ability Pharmaceuticals, S.L. Presents at Sachs Associates 17th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-26-2017 04:30 PM. Venue: The Congress Center, Basel, Switzerland.
Ability Pharmaceuticals Receives Orphan-Drug Designation for ABTL0812 from the US Food and Drug Administration for the Treatment of Pancreatic Cancer
Dec 15 16
Ability Pharmaceuticals announced that has received orphan-drug designation (ODD) for ABTL0812 from the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer. This regulatory milestone comes after the ODD for ABTL0812 in the pediatric cancer neuroblastoma granted by EMA and FDA in 2015. Pancreatic cancer is a life-threatening disease with a significant unmet medical need. The incidence of this cancer has markedly increased over the past several decades. Moreover, treatment options of pancreatic cancer are very limited due to its poor response to chemotherapy, radiation therapy and surgery as conventionally used. In preclinical studies, ABTL0812 have shown efficacy in pancreatic cancer as single agent and synergistic effect (by 8 to 90 times) in combination with taxanes, platinum compounds and gemcitabine, with induction of tumor regression without increasing the toxicity associated with chemotherapy. First-line therapy in patients with either locally advanced or metastatic pancreatic cancer includes these compounds, and administered in combination with ABTL0812 could greatly improve the treatment outcome. ABTL0812 is currently in phase 2 as first-line therapy in combination with chemotherapy in patients with endometrial or squamous lung cancer at Vall d’Hebron Institute of Oncology (VHIO) and Catalan Institute of Oncology (ICO) in Barcelona, Spain.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|